Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.

@article{Jong2001BleedingRW,
  title={Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.},
  author={P. C. M. Pasker-De Jong and Eric A Cohen and Wayne B. Batchelor and Charles Lazzam and Catherine Kreatsoulas and Madhu K Natarajan and Bradley H. Strauss},
  journal={American heart journal},
  year={2001},
  volume={141 2},
  pages={218-25}
}
BACKGROUND The bleeding risk associated with platelet glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) after full-dose thrombolysis for acute myocardial infarction (AMI) is unclear. We examined the risk and predictors of bleeding complications in patients with AMI who received abciximab during… CONTINUE READING